Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac) as a Booster Dose against COVID-19 in Indonesian Adults.

According to the WHO target product profile for COVID-19 vaccines, the vaccine in development should be indicated for active immunisation in all populations. Therefore, PT Bio Farma developed a candidate vaccine in a subunit protein recombinant platform to help overcome the issue. This trial was an observer-blind, randomised, prospective intervention study.

The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.

Background: Effort to search for the optimal COVID-19 treatment has continuously been attempted. Thymosin alpha-1 have immunomodulatory properties which may be beneficial in case of viral infection. This study's goal is to determine whether thymosin alpha-1 is effective in treating people with moderate-to-severe COVID-19.

Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia.

Background: Indonesia had the second-highest number of COVID-19 cases and deaths in South-East Asia. We aimed to determine the factors associated with this mortality and the effect of the recommended COVID-19 treatment regimen during the first 10 months of the epidemic.

Methods: This was a retrospective cohort study using secondary data from medical records.

Real-time RT-PCR Ct value is not associated with COVID-19 disease severity: an observational study in tertiary COVID-19 referral hospital of West Java, Indonesia.

Objective: Real-time reverse transcription-polymerase chain reaction (RT-PCR) is the gold standard examination to confirm coronavirus disease 2019 (COVID-19). This study aimed to determine the association between RT-PCR Ct value and COVID-19 clinical severity in the second week of illness.

Patients And Methods: This study was a cross-sectional study.